Delcath Systems Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
30,324.00
17,381.00
14,704.00
17,971.00
45,117.00
19,222
Depreciation, Depletion & Amortization
1,126.00
958.00
617.00
305.00
310.00
444
Other Funds
2,404.00
1,051.00
107.00
1,915.00
26,898.00
7,726
Funds from Operations
31,602.00
17,474.00
13,980.00
15,751.00
17,909.00
26,504
Changes in Working Capital
2,500.00
1,922.00
2,440.00
1,538.00
2,511.00
11,772
Net Operating Cash Flow
34,102.00
15,552.00
16,420.00
14,213.00
15,398.00
14,732
Capital Expenditures
142.00
44.00
170.00
258.00
524.00
Sale of Fixed Assets & Businesses
-
37.00
180.00
-
-
Net Investing Cash Flow
142.00
7.00
10.00
258.00
524.00
Issuance/Reduction of Debt, Net
-
-
-
31,226.00
2,310.00
Net Financing Cash Flow
41,702.00
4,869.00
8,655.00
33,609.00
2,325.00
Net Change in Cash
7,523.00
10,780.00
7,862.00
19,089.00
13,530.00
Free Cash Flow
34,244.00
15,596.00
16,590.00
14,471.00
15,922.00
Change in Capital Stock
41,702.00
4,869.00
8,655.00
2,383.00
15.00
Exchange Rate Effect
65.00
90.00
107.00
49.00
67.00

About Delcath Systems

View Profile
Address
1633 Broadway
New York New York 10019
United States
Employees -
Website http://www.delcath.com
Updated 07/08/2019
Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. It develops and commercializes Melphalan Hydrochloride for Injection, which is a proprietary product for use with the Delcath Hepatic Delivery System. The company was founded in August 1988 and is headquartered in New York, NY.